Charter Trust Co. boosted its position in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 4.6% during the 4th quarter, HoldingsChannel reports. The firm owned 38,411 shares of the biopharmaceutical company’s stock after buying an additional 1,690 shares during the quarter. Charter Trust Co.’s holdings in Bristol-Myers Squibb were worth $2,354,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Schwab Charles Investment Management Inc. grew its holdings in shares of Bristol-Myers Squibb by 5.3% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 5,402,341 shares of the biopharmaceutical company’s stock valued at $301,019,000 after acquiring an additional 270,982 shares in the last quarter. Cadinha & Co. LLC lifted its stake in shares of Bristol-Myers Squibb by 261.1% in the 2nd quarter. Cadinha & Co. LLC now owns 15,760 shares of the biopharmaceutical company’s stock valued at $878,000 after purchasing an additional 11,395 shares during the last quarter. New Jersey Better Educational Savings Trust lifted its stake in shares of Bristol-Myers Squibb by 40.0% in the 2nd quarter. New Jersey Better Educational Savings Trust now owns 14,000 shares of the biopharmaceutical company’s stock valued at $780,000 after purchasing an additional 4,000 shares during the last quarter. Partnervest Advisory Services LLC acquired a new stake in shares of Bristol-Myers Squibb in the 2nd quarter valued at $756,000. Finally, Foundry Partners LLC lifted its stake in shares of Bristol-Myers Squibb by 2,602.3% in the 2nd quarter. Foundry Partners LLC now owns 237,371 shares of the biopharmaceutical company’s stock valued at $13,226,000 after purchasing an additional 228,587 shares during the last quarter. Hedge funds and other institutional investors own 69.56% of the company’s stock.
In other news, EVP Thomas J. Jr. Lynch sold 5,300 shares of the business’s stock in a transaction dated Tuesday, December 12th. The shares were sold at an average price of $63.24, for a total transaction of $335,172.00. Following the transaction, the executive vice president now owns 9,251 shares in the company, valued at approximately $585,033.24. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, EVP Sandra Leung sold 156,582 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the transaction, the executive vice president now owns 584,373 shares in the company, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is owned by insiders.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.67 by $0.01. The firm had revenue of $5.45 billion during the quarter, compared to analyst estimates of $5.35 billion. Bristol-Myers Squibb had a net margin of 4.85% and a return on equity of 35.43%. The business’s revenue was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.63 EPS. equities analysts expect that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Shareholders of record on Friday, January 5th were given a dividend of $0.40 per share. This is a positive change from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend was Thursday, January 4th. This represents a $1.60 dividend on an annualized basis and a yield of 2.32%. Bristol-Myers Squibb’s payout ratio is currently 67.80%.
Several equities research analysts recently issued reports on the stock. Citigroup set a $78.00 price objective on shares of Bristol-Myers Squibb and gave the company a “buy” rating in a research note on Friday. Morgan Stanley raised shares of Bristol-Myers Squibb from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $51.56 to $78.00 in a research note on Thursday. Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a research note on Monday, January 29th. BMO Capital Markets set a $51.00 price objective on shares of Bristol-Myers Squibb and gave the company a “sell” rating in a research note on Wednesday. Finally, Leerink Swann lifted their price objective on shares of Bristol-Myers Squibb from $61.00 to $72.00 and gave the company an “outperform” rating in a research note on Monday, October 23rd. Three research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $66.73.
ILLEGAL ACTIVITY NOTICE: This report was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another domain, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/02/18/bristol-myers-squibb-co-bmy-shares-bought-by-charter-trust-co.html.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.